#CGTX
LightNews LightNews
secwatch.bsky.social
🚨 JUST IN: $CGTX
Cognition Therapeutics receives FDA alignment on pivotal trial design for zervimesine in DLB psychosis

#SEC #stocks #investing #CGTX #Regulatory
🔗 secwatch.observer
Cognition Therapeutics receives FDA alignment on pivotal trial design for zervimesine in DLB psychosis
June 24, 2026 at 11:57 AM
yurakuan.bsky.social
#戦争反対

高市早苗とネトウヨが日本を台湾有事の最前線へ引きずり出す―官僚の知恵を捨てた「独走答弁」の末路 。 - YouTube
www.youtube.com/watch?v=cgTX...
高市早苗とネトウヨが日本を台湾有事の最前線へ引きずり出す―官僚の知恵を捨てた「独走答弁」の末路 。
YouTube video by 三好りょう【公式】
www.youtube.com
April 25, 2026 at 5:00 PM
biostock.bsky.social
🟢 #$CGTX — Clinical Milestone
FDA Written Feedback Received - Alignment on Pivotal Trial Design for DLB Psychosis NDA
Cognition Therapeutics received written FDA feedback (meeting minutes) following the May 2026 FDA meeting. The FDA agreed that DLB psychosis is…

https://biostock.app/symbols/CGTX
June 24, 2026 at 11:42 AM
marketwirenews.com
Breaking News: ( NASDAQ: #CGTX ) Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

#StockMarket #News
October 29, 2024 at 5:15 PM
biopharmcatalyst.bsky.social
$PSTX announced a merger agreement with $RHHBY for $9.00 per share, with a non-tradeable CVR offering up to $4.00

See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/po...

$ALEC $ARWR $DRUG $SRPT $CGTX $QLGN $PTIX $AMGN
November 26, 2024 at 1:26 PM
rieke.lt
I edited a video of a quiz we did a few months back with captain_awes0me, @tonykordatos.bsky.social and @fearful.bsky.social

Major shoutouts to @deliciousjames.bsky.social for the idea (and ONLY SOME PUZZLES), will do better next time haha

www.youtube.com/watch?v=CGTX...
They didn't know what to expect with this quiz
YouTube video by Riekelt
www.youtube.com
September 11, 2025 at 9:18 PM
stocktitan.net
#CGTX Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-analysis-correlates-biomarker-changes-with-4iggii7fn1lz.html
November 25, 2024 at 12:31 PM
biopharmcatalyst.bsky.social
$SAVA reported that topline data from its Phase 3 ReThink-ALZ study of simufilam for Alzheimer’s disease failed to meet all endpoints

See More Pre-market Movers 👇
www.biopharmcatalyst.com/news/2024/ca...

$CTXR $BBIO $CGTX $ALUR $ONCT $ELAB $CMAX $DRRX $RNAZ $EYEN
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Profit on the stock market by investing in biotech stocks
www.biopharmcatalyst.com
November 25, 2024 at 1:32 PM
gjrboston.bsky.social
BREAKING: Fat Loaf has bought 50,000 shares in Cognition Therapeutics, Inc. (CGTX)

Carry On.
May 31, 2026 at 8:18 PM
cognition-tx.bsky.social
$CGTX CEO, Lisa Ricciardi, will present at 1:25 p.m. ET today at the 2026 @Jefferies Global Healthcare Conference. Find a link to the live and archived presentation on the Cognition Therapeutics IR webpage: ir.cogrx.com/events/

#JefferiesHealthcare #ThoughtLeadership #BiotechInvesting #DLB
June 4, 2026 at 1:10 PM
dekmartrades.bsky.social
$CGTX Cognition Therapeutics Reports Topline Results Showing Oral Zervimesine (CT1812) Reduced Lesion Growth in Phase 2 Study in Geographic Atrophy

foxrunner.com?fpr=newsscan...
May 8, 2025 at 11:35 AM
stocktitan.net
#CGTX Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-provides-regulatory-update-on-zervimesine-2u9pljcrti7d.html
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
Cognition Therapeutics (NASDAQ: CGTX) announced key regulatory developments for its drug zervimesine (CT1812). The company has scheduled an end-of-Phase 2 meeting with the FDA on July 9, 2025, to discuss results from the SHINE study in mild-to-moderate Alzheimer's disease and plans for Phase 3 trials.Additionally, following positive Phase 2 SHIMMER study results, CGTX has submitted applications for both breakthrough therapy designation and IND approval for Dementia with Lewy Bodies (DLB). The company is also progressing with an expanded access program (EAP) for DLB patients, with high interest among former SHIMMER study participants.
www.stocktitan.net
June 25, 2025 at 11:30 AM
stocktitan.net
#CGTX Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-ceo-participating-in-longwood-and-sachs-y1qqzqr7ezma.html
Cognition Therapeutics Advances DLB Treatment After Positive Phase 2 Results, CEO to Present at JPM Week
Cognition Therapeutics reports breakthrough in dementia with Lewy body treatment, secures 'zervimesine' name approval, and prepares for FDA meeting on Alzheimer's study results.
www.stocktitan.net
January 8, 2025 at 9:14 PM
marketwirenews.com
Just In: ( NASDAQ: #CGTX ) Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

#StockMarket #News
December 18, 2024 at 3:05 PM
dporjude.bsky.social
youtube.com/watch?v=CGtX...
Prof. Shahid Bolsen Urgent WARNING To White America That Nobody Was Ready For: Babylon Has Fallen
YouTube video by Afripost
youtube.com
June 7, 2026 at 1:58 PM
stocktitan.net
#CGTX Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-presents-results-at-ad-pd-2025-showing-impact-qkhlljwyq8bb.html
Breakthrough: Cognition's Alzheimer's Drug Reduces Multiple Disease Markers in Phase 2 Trial
Phase 2 trial reveals Zervimesine reduces key Alzheimer's biomarkers including GFAP and NfL. Stronger effects seen in specific patient subgroup. Full analysis inside.
www.stocktitan.net
April 1, 2025 at 11:30 AM
marketwirenews.com
BREAKING NEWS: ( NASDAQ: #CGTX ) Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease

#StockMarket #News
August 22, 2024 at 4:10 PM
cognition-tx.bsky.social
Psychosis - #hallucinations and #delusions - is common in DLB. $CGTX CEO, Lisa Ricciardi discusses the debilitating nature of DLB #psychosis in this video interview with Fierce Biotech: www.fiercebiotech.com/sponsored/tr...

#DementiaResearch #BrainHealth #LewyStrong #DementiawithLewyBodies
May 24, 2026 at 10:45 PM
biopharmcatalyst.bsky.social
$CGTX provided an update on a biomarker1 analysis from the Phase 2 ‘SHINE' study in mild-to-moderate #Alzheimer's disease. This new analysis focused on plasma samples from all participants who entered the study with lower levels of plasma p-tau2172

#biotech

www.biopharmcatalyst.com/company/CGTX...
Biotech catalyst calendars and drug pipelines • BioPharmCatalyst
Profit on the stock market by investing in biotech stocks
www.biopharmcatalyst.com
November 25, 2024 at 1:11 PM
stocktitan.net
#CGTX Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

https://www.stocktitan.net/news/CGTX/cognition-therapeutics-announces-positive-results-in-phase-2-study-xs2tu8co26eh.html
Cognition Therapeutics' DLB Drug Shows Remarkable 82% Symptom Reduction in Phase 2 Trial Results
Breakthrough clinical data reveals CT1812's strong efficacy in treating dementia with Lewy bodies, showing major improvements in behavior, cognition, and movement measures.
www.stocktitan.net
December 18, 2024 at 12:23 PM
cognition-tx.bsky.social
See $CGTX CMO, Anthony Caggiano, MD, PhD discuss Phase 2 #DLB results in an interview with Psychiatric Times: buff.ly/0xjBxb2

"The strongest data that we had were within the behavioral symptoms - things like hallucinations, delusions, anxiety, agitation."

#DLBPsychosis #LewyStrong #Psychosis
May 29, 2026 at 5:33 PM
biopharmcatalyst.bsky.social
BioPharmCatalyst Weekly #Watchlist

Key catalysts left for the quarter; Countdown to the end of the quarter

$LXRX $GALT $AVXL $BGNE $PGEN $XERS $CGTX $PBYI $CRVO $NUVB

www.biopharmcatalyst.com/news/2024/ke...

#biotech #stocks
December 6, 2024 at 9:41 PM
cognition-tx.bsky.social
The #CGTX team is presenting an analysis at #ADPD2026 showing that Phase 2 'SHIMMER' #DLB participants on #zervimesine had a 102% slowing of decline relative to placebo. #Pressrelease: tinyurl.com/26rh26be

#DementiaWithLewyBodies #LewyBodyDementia #Dementia #LewyStrong #Psychosis #Neuroscience
March 18, 2026 at 12:11 AM
marketwirenews.com
Breaking News: ( NASDAQ: #CGTX ) Analyses from Cognition's Positive Phase 2 'SHINE' Study of CT1812 in Mild-to-Moderate Alzheimer's Disease will be Presented in a Podium Presentation at CTAD

#StockMarket #News
October 23, 2024 at 3:20 PM
kevynmenezes.bsky.social
@phluttilippe.bsky.social, não é oficial, mas já dá para ir matando a vontade até a Sega tomar vergonha na cara e lançar essa pedrada oficialmente.

www.youtube.com/watch?v=Cgtx...
STRANGER THAN HEAVEN CAST MUSIC TRAILER (In the meantime....)
YouTube video by Mariostyle
www.youtube.com
May 10, 2026 at 1:57 AM